{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T19:02:16Z","timestamp":1779217336751,"version":"3.51.4"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,30]]},"DOI":"10.7759\/cureus.106151","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T21:59:04Z","timestamp":1774907944000},"source":"Crossref","is-referenced-by-count":1,"title":["Hydralazine-Induced Antineutrophil Cytoplasmic Antibody Vasculitis Causing Gastroduodenal Artery Perforation"],"prefix":"10.7759","author":[{"given":"Katherine N","family":"Gonzalez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Faradji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyle","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shivani","family":"Desai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huda N","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaimin","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.17-1-60","article-title":"ANCA-associated vasculitis","volume":"17","author":"Yates M","year":"2017","unstructured":"Yates M, Watts R. ANCA-associated vasculitis. Clin Med (Lond). 2017, 17:60-4. 10.7861\/clinmedicine.17-1-60","journal-title":"Clin Med (Lond)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1590\/2175-8239-jbn-3858","article-title":"Hydralazine-associated adverse events: a report of two cases of hydralazine-induced ANCA vasculitis","volume":"40","author":"Zuckerman R","year":"2018","unstructured":"Zuckerman R, Patel M, Costanzo EJ, Dounis H, Haj RA, Seyedali S, Asif A. Hydralazine-associated adverse events: a report of two cases of hydralazine-induced ANCA vasculitis. J Bras Nefrol. 2018, 40:193-7. 10.1590\/2175-8239-jbn-3858","journal-title":"J Bras Nefrol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.35306","article-title":"Hydralazine-induced vasculitis","volume":"15","author":"Gandhi P","year":"2023","unstructured":"Gandhi P, Khurana B, Munjal RS, Sekar A, Gandhi RG. Hydralazine-induced vasculitis. Cureus. 2023, 15:e35306. 10.7759\/cureus.35306","journal-title":"Cureus"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-020-02378-w","article-title":"Hydralazine-induced antineutrophil cytoplasmic antibody-associated vasculitis with pulmonary-renal syndrome: a case report","volume":"14","author":"Al-Abdouh A","year":"2020","unstructured":"Al-Abdouh A, Siyal AM, Seid H, Bekele A, Garcia P. Hydralazine-induced antineutrophil cytoplasmic antibody-associated vasculitis with pulmonary-renal syndrome: a case report. J Med Case Rep. 2020, 14:47. 10.1186\/s13256-020-02378-w","journal-title":"J Med Case Rep"},{"key":"ref5","article-title":"Drug-induced vasculitis: a clinical and pathological review","volume":"70","author":"Radi\u0107 M","year":"2012","unstructured":"Radi\u0107 M, Martinovi\u0107 Kaliterna D, Radi\u0107 J. Drug-induced vasculitis: a clinical and pathological review. Neth J Med. 2012, 70:12-7.","journal-title":"Neth J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.03.029","article-title":"Anti-neutrophil cytoplasmic antibody associated glomerulonephritis complicating treatment with hydralazine","volume":"100","author":"Santoriello D","year":"2021","unstructured":"Santoriello D, Bomback AS, Kudose S, et al.. Anti-neutrophil cytoplasmic antibody associated glomerulonephritis complicating treatment with hydralazine. Kidney Int. 2021, 100:440-6. 10.1016\/j.kint.2021.03.029","journal-title":"Kidney Int"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200002)43:2<405::AID-ANR22>3.0.CO;2-5","article-title":"Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis: prevalence among patients with high titers of antimyeloperoxidase antibodies","volume":"43","author":"Choi HK","year":"2000","unstructured":"Choi HK, Merkel PA, Walker AM, Niles JL. Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis: prevalence among patients with high titers of antimyeloperoxidase antibodies. Arthritis Rheum. 2000, 43:405-13. 10.1002\/1529-0131(200002)43:2&lt;405::AID-ANR22&gt;3.0.CO;2-5","journal-title":"Arthritis Rheum"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2018.01.005","article-title":"Hydralazine-associated vasculitis: overlapping features of drug-induced lupus and vasculitis","volume":"48","author":"Kumar B","year":"2018","unstructured":"Kumar B, Strouse J, Swee M, Lenert P, Suneja M. Hydralazine-associated vasculitis: overlapping features of drug-induced lupus and vasculitis. Semin Arthritis Rheum. 2018, 48:283-7. 10.1016\/j.semarthrit.2018.01.005","journal-title":"Semin Arthritis Rheum"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.10.008","article-title":"KDIGO 2024 Clinical Practice Guideline for the Management of Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis","volume":"105","year":"2024","unstructured":"KDIGO 2024 Clinical Practice Guideline for the Management of Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis. Kidney Int. 2024, 105.S71-S116. 10.1016\/j.kint.2023.10.008","journal-title":"Kidney Int"},{"key":"ref10","article-title":"Hemoptysis: evaluation and management","volume":"91","author":"Earwood JS","year":"2015","unstructured":"Earwood JS, Thompson TD. Hemoptysis: evaluation and management. Am Fam Physician. 2015, 91:243-9.","journal-title":"Am Fam Physician"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2023.02.003","article-title":"KDOQI US Commentary on the 2021 KDIGO Clinical Practice Guideline for the Management of Glomerular Diseases","volume":"82","author":"Beck LH Jr","year":"2023","unstructured":"Beck LH Jr, Ayoub I, Caster D, et al.. KDOQI US Commentary on the 2021 KDIGO Clinical Practice Guideline for the Management of Glomerular Diseases. Am J Kidney Dis. 2023, 82:121-75. 10.1053\/j.ajkd.2023.02.003","journal-title":"Am J Kidney Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/447110-hydralazine-induced-antineutrophil-cytoplasmic-antibody-vasculitis-causing-gastroduodenal-artery-perforation","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T21:59:05Z","timestamp":1774907945000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/447110-hydralazine-induced-antineutrophil-cytoplasmic-antibody-vasculitis-causing-gastroduodenal-artery-perforation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,30]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.106151","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,30]]}}}